7144-91-4

Usage

Uses

Used in Drug Development:
(2Z)-4-oxo-4-[(pyridin-4-ylmethyl)amino]but-2-enoic acid is used as a building block for the synthesis of novel pharmaceutical compounds. Its unique structure and potential biological activity make it a promising candidate for the development of new drugs with therapeutic applications.
Used in Medicinal Chemistry Research:
(2Z)-4-oxo-4-[(pyridin-4-ylmethyl)amino]but-2-enoic acid is used as a research tool in medicinal chemistry to study its interactions with biological targets and to understand its pharmacological effects. This knowledge can contribute to the design and optimization of new drugs with improved efficacy and safety profiles.
It is important to handle and store (2Z)-4-oxo-4-[(pyridin-4-ylmethyl)amino]but-2-enoic acid with care, as it may pose health and environmental risks due to its chemical properties. Proper safety measures should be taken to minimize any potential hazards associated with (2Z)-4-oxo-4-[(pyridin-4-ylmethyl)amino]but-2-enoic acid.

Upstream product

• 108-31-6 maleic anhydride 
• 3731-53-1 4-(aminomethyl)pyridine 

Downstream Products

• 46277-44-5 1-[(pyridin-4-yl)methyl]pyrrole-2,5-dione 

Relevant academic research and scientific papers

Organoruthenium and osmium anticancer complexes bearing a maleimide functional group: Reactivity to cysteine, stability, and cytotoxicity

Targeted delivery provides a means to overcome the systemic toxicity of cancer chemotherapeutics. Maleimide functionalization of anticancer-active metal complexes allows their site-selective covalent conjugation to human serum albumin (HSA) to exploit passive targeting to the tumor site through the enhanced permeability and retention (EPR) effect. By incorporating the maleimide moiety in the monodentate N-donor coligands, a series of [MII(cym)X2] (M = Ru, Os; cym = η6-pcymene; X = Cl2, Br2, I2, oxalate) complexes was synthesized and characterized. The influence of the metal center, η6-arene, and leaving group X on the chemical and biological properties was studied. The compounds exhibited low stability in dimethyl sulfoxide (DMSO) but were more stable in the 5% aqueous DMSO solution used in biological assays. Incubation with cysteine as a model for thiol-containing biomolecules demonstrated high reactivity of the maleimide with the thiol group. In in vitro anticancer assays in human colorectal, non-small-cell lung, and cervical carcinoma cells the complexes were good to moderately active with the lowest IC50 value at 8 μm for an osmium-iodido complex.